Bisphosphonates, Osteoporosis, and Osteonecrosis of the Jaw: A Critical Review of a Large Nested Case–Control Study

Bergdahl, 2013, Evaluation of an algorithm ascertaining cases of osteonecrosis of the jaw in the Swedish National Patient Register, Clin Epidemiol, 5, 1, 10.2147/CLEP.S37664 Polymeri, 2015, Bisphosphonates: clinical applications and adverse events in dentistry, Oral Health Prev Dent, 13, 289 Oringer, 2002, Modulation of the host response in periodontal therapy, J Periodontol, 73, 460, 10.1902/jop.2002.73.4.460 Jeffcoat, 1996, Alveolar bone loss and osteoporosis: evidence for a common mode of therapy using the bisphosphonate alendronate, 365 Palaska, 2009, Bisphosphonates and time to necrosis development, Oncologist, 14, 1154, 10.1634/theoncologist.2009-0115 Cartsos, 2008, Bisphosphonate use and the risk of adverse jaw outcomes: a medical claims study of 714,217 people, J Am Dent Assoc, 139, 23, 10.14219/jada.archive.2008.0016 Zavras, 2006, Bisphosphonates are associated with increased risk for jaw surgery in medical claims data: is it osteonecrosis?, J Oral Maxillofac Surg, 64, 917, 10.1016/j.joms.2006.02.011 Ruggiero, 2009, American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws—2009 update, J Oral Maxillofac Surg, 67, 2 Ernster, 1994, Nested case-control studies, Prev Med, 23, 587, 10.1006/pmed.1994.1093 Zavras, 2008, Population-based studies in the U.S: ONJ among patients with osteoporosis or cancer [abstract]